Firstly, we proposed for the first time that FMO2 can affect the effect of immunotherapy as a prognostic marker and SFRP1 could be a predictive marker of chemotherapy, hormone therapy, and anti-HER2 therapy on breast cancer. Here, ERBB2 is linked to breast cancer.